Please login to the form below

Not currently logged in
Email:
Password:

GSK’s rare diseases head Marc Dunoyer to join AZ

Appointed executive VP, global portfolio and product strategy amid global restructure

GSK%u2019s rare disease head Marc Dunoyer to join AZAstraZeneca (AZ) has hired former head of GSK's rare diseases business Marc Dunoyer to support its global restructuring programme.

Dunoyer joins AZ as executive VP, global portfolio and product strategy as it prepares to axe more than 5,000 positions as part of a three-year strategy to return to growth.

He has a strong pedigree in pharma, serving at GSK for more than a decade, including spells as chairman of GSK Japan, president for Asia Pacific and Japan and his most recent role as global head of rare diseases.

In its growth strategy announcement, AZ said it was looking to expand in Asian markets, including Japan, and Dunoyer's experience will be helpful.

“I'm delighted Marc is joining us in this pivotal new role aimed at bringing greater integration across our R&D, commercial and business development activities,” said AstraZeneca's CEO Pascal Soriot, who joined from fellow big pharma rivals Roche in 2012.

He added: “Marc is a first-rate leader with a proven track record in driving business growth and he brings to AstraZeneca a wealth of international operating experience, in particular in the important Asia region, combined with outstanding strategic skills.”

Dunoyer will assume the role in the second quarter of 2013, and will be a member of AZ's senior executive team reporting directly to Soriot.

25th March 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics